Article Text

Download PDFPDF
Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @Harjeevsudan

  • Contributors KJ has full access to all data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis. KJ and PML conceived the study. KJ, PML, SL, ZJS and FR designed the study. ZJS and HS were responsible for clinical data. PML, FR, LG and AM were responsible for serological data. PNL was responsible for neutralisation data. KJ, PML, SL, ZJS and FR analysed the data. ZJS drafted the manuscript. All authors interpreted the data and provided critical revisions of the manuscript for important intellectual content. All authors approved the final draft of the manuscript.

  • Funding KJ is a Senior Clinician Scientist supported by the Children with Intestinal and Liver Disorders (CHILD) Foundation and the BC Children’s Hospital Research Institute Clinician Scientists Award Program, University of British Columbia. PML is supported by a salary award from the BC Children’s Hospital Foundation through the Investigator Grant Award Program. ZJS is supported by the Moffat Family Foundation. FR is funded by the Deutsche Forschungsgemeinschaft (German Research Foundation), award number RE 4598/1-1.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; externally peer reviewed.